Literature DB >> 19444262

A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant.

Kiang Chong1, Ketan Dhatariya.   

Abstract

BACKGROUND: A 31-year-old woman with an 11-year history of poorly controlled type 1 diabetes mellitus was admitted with severe vomiting and ketoacidosis. The patient had been admitted to hospital on 14 occasions in the past 3 years for diabetic ketoacidosis precipitated by intractable vomiting, and she had been diagnosed with gastroparesis 2 years previously. INVESTIGATIONS: Assessment of the patient's response to standard treatments for diabetic gastroparesis. These approaches involved tight glycemic control that included subcutaneous insulin infusion via a pump, correction of electrolyte disturbances, use of standard antiemetic and promotility agents, somatostatin-analog treatment, intrapyloric injection of botulinum toxin, and insertion of a percutaneous jejunal feeding tube. DIAGNOSIS: Severe diabetic gastroparesis refractory to standard treatments. MANAGEMENT: The neurokinin-receptor antagonist aprepitant was started and her vomiting stopped within 24 h. This treatment was successfully continued for 4 months until a gastric electrical stimulation device was inserted, which enabled aprepitant treatment to be withdrawn and the percutaneous jejunostomy feeding tube to be removed. This successful treatment led to a substantial improvement in the patient's quality of life and overall glycemic control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444262     DOI: 10.1038/nrendo.2009.50

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  16 in total

1.  Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis.

Authors:  Z Lin; I Sarosiek; J Forster; R W McCallum
Journal:  Neurogastroenterol Motil       Date:  2006-01       Impact factor: 3.598

2.  Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations.

Authors:  Zhiyue Lin; Chris McElhinney; Irene Sarosiek; Jameson Forster; Richard McCallum
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 3.  Clinical practice. Diabetic gastroparesis.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

4.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

5.  Diabetic gastroparesis in association with autonomic neuropathy and microvasculopathy.

Authors:  M Cem Koçkar; I Kaan Kayahan; Nüket Bavbek
Journal:  Acta Med Okayama       Date:  2002-10       Impact factor: 0.892

6.  Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis.

Authors:  I Soykan; B Sivri; I Sarosiek; B Kiernan; R W McCallum
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

7.  A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans.

Authors:  J L Madsen; S Fuglsang
Journal:  Aliment Pharmacol Ther       Date:  2008-01-16       Impact factor: 8.171

8.  The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.

Authors:  Brian E Lacy; Michael D Crowell; Ann Schettler-Duncan; Carole Mathis; Pankaj J Pasricha
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

9.  Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study.

Authors:  R W McCallum; O Cynshi
Journal:  Aliment Pharmacol Ther       Date:  2007-10-15       Impact factor: 8.171

10.  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

Authors:  R M Navari; R R Reinhardt; R J Gralla; M G Kris; P J Hesketh; A Khojasteh; H Kindler; T H Grote; K Pendergrass; S M Grunberg; A D Carides; B J Gertz
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

View more
  11 in total

Review 1.  Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years.

Authors:  Purna Kashyap; Gianrico Farrugia
Journal:  Gut       Date:  2010-09-25       Impact factor: 23.059

Review 2.  Gastroparesis: pathogenesis, diagnosis and management.

Authors:  William L Hasler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-19       Impact factor: 46.802

Review 3.  Treatment of refractory diabetic gastroparesis: Western medicine and traditional Chinese medicine therapies.

Authors:  Bing Pang; Qiang Zhou; Jun-Ling Li; Lin-Hua Zhao; Xiao-Lin Tong
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 4.  [Gastroparesis. Definition, diagnostics, and therapy].

Authors:  U von Arnim
Journal:  Internist (Berl)       Date:  2015-06       Impact factor: 0.743

5.  Clinical guideline: management of gastroparesis.

Authors:  Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

6.  Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.

Authors:  Deepti Jacob; Irene Busciglio; Duane Burton; Houssam Halawi; Ibironke Oduyebo; Deborah Rhoten; Michael Ryks; W Scott Harmsen; Michael Camilleri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-08-16       Impact factor: 4.052

Review 7.  Nausea: a review of pathophysiology and therapeutics.

Authors:  Prashant Singh; Sonia S Yoon; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 8.  Diabetic gastroparesis: functional/morphologic background, diagnosis, and treatment options.

Authors:  Viktor J Horváth; Ferenc Izbéki; Csaba Lengyel; Péter Kempler; Tamás Várkonyi
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

9.  Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.

Authors:  Raghunandan Reddy Kura; Eswar Kumar Kilari; Mastan Shaik
Journal:  PeerJ       Date:  2018-05-22       Impact factor: 2.984

Review 10.  Nausea and Vomiting in 2021: A Comprehensive Update.

Authors:  Matthew Heckroth; Robert T Luckett; Chris Moser; Dipendra Parajuli; Thomas L Abell
Journal:  J Clin Gastroenterol       Date:  2021-04-01       Impact factor: 3.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.